Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage trial (n=250) demonstrated that subjects injected with Vivitrol (naltrexone for extended-release injectable suspension) once a month were more likely to pass a urine test compared to recipients of a placebo injection. Furthermore, subjects reported a lower craving for drugs, and half the subjects came clean in at least 90% of their drug tests.   The subjects were addicted to opioid drugs including heroin. Before enrolling for the trial, they had to stay away from drugs for at least a week. The most common adverse event affecting patients during the study were inflammation of the nose and throat in addition to insomnia.   The positive results have formed the basis of Alkermes’ decision to file a supplemental new ...

AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% and 10% respectively, all other segments increased their revenues. AstraZeneca recorded more than 26% of ...

BioElectronics Corp. is focused on producing inexpensive, drug–free, anti-inflammatory medical devices and patches. The company’s wafer thin patches contain an embedded microchip and battery that deliver pulsed electromagnetic energy. BioElectronics markets and sells its products under the brand names ActiPatch™ and RecoveryRx™.

The dermal patch delivery system has created numerous new product opportunities for treating chronic and acute inflammatory conditions. The market potential is estimated at $10 billion, or 400 million incidents, worldwide. The value proposition of BioElectronics’ ActiPatch is the delivery of drug-free therapy that reduces pain and inflammation, while accelerating healing by 30% to 50%.

The company’s products have broad regulatory market clearance in many international countries for the relief of pain, swelling, and accelerated healing. BioElectronics’ strategy is to identify one strong distributor in a given country and give this distributor country-wide distribution rights in return for minimum yearly quotas. To date the Company has signed agreements with

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday November 11, 2009

DrStockPick.com Stock Report!

**************************************************************

NCST, NUCRYST Pharmaceuticals Corp.

NCST develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology.

NCST reported the Execution of a definitive agreement with subsidiaries of Smith & Nephew plc. for the sale to Smith & Nephew of substantially all of NCST’s operations and assets including all rights to its proprietary nanocrystalline silver technology for cash consideration of US$21 million plus the value of working capital and subject to certain adjustments. The closing of the Sale Transaction is subject to

...

Following the recent merger of Pfizer (PFE) and Wyeth, a U.S. court imposed a huge fine on the company’s subsidiary Pharmacia & Upjohn for fraudulent marketing of its painkiller Bextra (valdecoxib). The penalty of $1.195 billion was the largest criminal fine ever imposed in the U.S. In addition, a criminal forfeiture of $105 million was enforced on the company.   In September, Pfizer had agreed to pay an additional $1 billion along with interest to settle civil allegations related to fraudulent promotion of four drugs – Bextra, the anti-psychotic drug Geodon, the antibiotic Zyvox and the anti-epileptic drug Lyrica – as well as claims that the company paid kickbacks to physicians to prescribe these and nine other drugs.   In addition to the huge penalty, Pfizer had to agree to comply with the terms of a new and significantly expanded corporate compliance program. It seeks to ensure that ...

Yesterday, Dynavax Technologies Corp. (DVAX) announced that it has resumed the late-stage registration trial of its hepatitis B (HBV) vaccine Heplisav in patients with chronic kidney disease. The trial will enroll 600 patients. Heplisav will be tested against GlaxoSmithKline plc’s (GSK) Engerix-B. The company intends to begin another late-stage registration trial in adults over 40 years of age in early 2010. Dynavax expects to complete both trials within the next 2 years. Management expects the vaccine to hit the market by the end of 2012 or early 2013.   As a reminder, Heplisav was on clinical hold in the U.S since March 17, 2008 following the occurrence of the severe adverse event (SAE) of Wegener's granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the US. Wegener's granulomatosis is an uncommon disease which results in the inflammation of blood vessels. ...

Earlier this month, Anadys Pharmaceuticals, Inc. (ANDS) announced the commencement of dosing in a 12- week phase II trial with ANA598 in hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. The study is expected to provide important data at the end of this year and in the first two quarters of 2010. A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S. Chronic hepatitis C virus (HCV) affects approximately 3.2 million people ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Celebrating the stories, culture and heritage of America’s Deaf and Hard-of-Hearing Community, Purple Communications, Inc. (Nasdaq: PRPL) will honor National Champion Motocross Rider and Floridian, Ashley Fiolek for being a role model to deaf youth nationwide and her accomplishments as a stellar athlete in a male-dominated sport. Community members are encouraged to join in the celebration on September 19, 2009 at the Hilton St. Petersburg Carillon Park, 950 Lake Carillon Drive in Saint Petersburg, FL. The event will feature

...

Access Pharmaceuticals Inc. develops and commercializes proprietary products for the treatment and care of cancer patients. The company today announced an agreement with commercial manufacturer Accupac Inc. to produce and distribute Access’ FDA-approved MuGard in the North American market.

MuGard is a mucoadhesive oral wound rinse for patients in radiation and chemotherapy that often-time develop mucositis, or the inflammation of mucous membranes along the lining of the digestive track, including the mouth. The company says the market for treating oral mucositis is estimated at $5 billion worldwide.

“Access is moving forward with the development of MuGard in North America,” Jeffrey B. Davis, Access’ president and CEO stated in the press release. “Establishing our relationship with Accupac, a leader in liquid contract manufacturing, is critical to our successful commercialization of MuGard. In addition, Access is currently evaluating potential eMarketing partners as well as potential co-promotion or other licensing opportunities.”

According to Access,

...

Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected to be released at the end of this year and in the first two quarters of 2010.

A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S.

Chronic hepatitis C virus (HCV) affects nearly 3.2 million people in the United States and about 170 million people

...